Mehdi AINOUCHE

🌟 From Biologics To Biobetters: A Leap For Better Patient Outcomes🌟 In the ever-evolving landscape of biotechnology, the term "biobetter" is gaining momentum, and for good reason. A recent report by Celltrion Healthcare France has shed light on the significant advantages biobetters hold over biosimilars and biologics. 🔬 What Are Biobetters? Biobetters are enhanced versions of existing biologics, engineered to improve various attributes such as delivery routes, efficacy, safety, and patient tolerance. Unlike biosimilars, which are merely equivalent to their reference biologics, “biobetters” introduce tangible improvements. These can include better glycosylation profiles, modified Fc fragments, extended half-lives, and reduced immunogenicity. 💡 Why Biobetters Excel ·        Improved Efficacy and Safety: Clinical results often show enhanced effectiveness and a safer profile. ·        Better Patient Experience: Enhanced pharmacokinetics, improved formulations, and more convenient administration methods. ·        Innovation and Patent Benefits: While the development of biobetters can be costly and time-consuming, they offer the possibility of new patents, ensuring extended market exclusivity and innovation incentives. 📈 The Future is Biobetters As we look towards the future of medicine, biobetters represent a significant leap forward. They hold the potential to provide better therapeutic outcomes and a higher quality of life for patients. At Plantibodies, we're at the forefront of this revolution. Our mission is to convert blockbuster IV biologics into oral capsules, maintaining efficacy while reducing toxicity. This not only extends the therapeutic window but also rejuvenates the drug's patent life, ensuring continued innovation and accessibility. Join us on this journey to transform and improve healthcare! #Biotechnology #Biobetters #HealthcareInnovation #Plantibodies #Sorbonne #SorbonneVentures Interested to learn more about Biobetters? Read the following Celltrion article: https://lnkd.in/ekmNryW4

29

1 commentaire

𝐁𝐢𝐨𝐩𝐡𝐲𝐭𝐢𝐬 𝐑𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐟𝐨𝐫 𝐏𝐡𝐚𝐬𝐞 𝟐 𝐎𝐁𝐀 𝐒𝐭𝐮𝐝𝐲 𝐢𝐧 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 Biophytis SA (Euronext Growth Paris) BIOPHYTIS - Live Healthier Longer, a clinical-stage biotech company focused on age-related diseases, announced FDA Investigational New Drug (IND) approval for its phase 2 OBA study in obesity using BIO101 (20-hydroxyecdysone).The study's primary objective is to measure muscle strength improvement in lower limbs, assessed by the knee extension test. Secondary endpoints include mobility (6-minute walk test) and body composition (fat and lean mass). The principal investigator, Marc-André Cornier, President-elect of the American Obesity Society and Professor of Medicine at the Medical University of South Carolina, expressed his enthusiasm about the approval, emphasizing the importance of studying new therapies to reduce muscle mass loss and weakness associated with incretin-based therapies. The multicenter study will commence in mid-2024 in the USA, potentially extending to Europe, with preliminary results expected in 2025. Biophytis is seeking funding and partnerships to complete the study. Stanislas Veillet Stanislas Veillet, CEO of Biophytis, highlighted the significance of obesity as a major medical challenge and growth opportunity. He noted that the obesity treatment market is projected to grow from $6 billion in 2023 to $100 billion by 2030. The IND approval is a crucial step for rapid progress in this indication and attracting new pharmaceutical partners. Veillet expressed confidence that BIO101 could become a reference treatment for preserving muscle mass, strength, and function in obese patients treated with GLP-1 RAs. #Biotechnology #ClinicalTrials #ObesityTreatment #FDAApproval #MedicalResearch #BIO101 #Pharma #HealthInnovation #MuscleStrength #Healthcare

1

/ FUND RAISING /   Société de Bourse Gilbert Dupont is delighted to announce that MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, has successfully closed a fund raising for a total aggregate amount of €19.2m in the context of the (a) Primary Offering through (i) a reserved offering for the benefit of specific categories of investors for c.€17.3m and (ii) a public offering, via the PrimaryBid platform for c.€0.9m and (b) the sale of 125,000 existing ordinary shares for €1m.   The net proceeds from the Primary Offering, which are estimated to be approximately €17.3m, will be used to fund the company’s R&D activities, covering completion of the Phase 3 trial for MaaT013 in Europe, including top-line results/primary endpoint in mid Q4 2024, continuing the pipeline development, including the initiation of Phase 3 trial activities for MaaT013 in the US and the broadening of the Phase 2b trial with MaaT033 across Europe and for working capital and other general corporate purposes, including repayment of current debts.   Société de Bourse Gilbert Dupont acted as Joint Bookrunner. We thank Herve Affagard, MBA, Eng., Sian Crouzet, Guilhaume Debroas, Ph.D. and all the MaaT Pharma team for their trust.  👉 Link to the press release : https://lnkd.in/eX6iG4Hz   MaaT Pharma #Healthcare #ECM #finance #Bourse #Smallandmidcap #Markets

36

1 commentaire

DTx FRANCE 2024 Proud to be International Partner of #DTxFrance 2024, the French and European event on Digital Therapeutics #DTx https://lnkd.in/eMm8Y6M7. With the adoption of #Pecan, France is on its way to becoming a #DTxNation and a new reference for Digital Therapeutics and patient-facing digital health technologies at European and international level. Mathilde Pasko Kamal Kishor Kénnètth Jósèph, PharmD, MBA Kyle Dardashti

11

How to save a critical medicine? At Delbert Pharma we follow 3 main steps: ✅ UPDATE the marketing authorization file to meet the requirements of the health authorities 🏭 RELAUNCH production by identifying the right supplier in France or Europe and aligning manufacturing processes with GMP 🤝 COLLABORATE closely at each stage of the project with health authorities, our mission translates into a long-term commitment, sometimes over several years, and it is at this cost that we take up the challenge of preserving pharmaceutical heritage. #DelbertPharma #MissionDrivenCompany #PatientsFirst

28

We are pleased to share a new article: A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS) published in Annals of Hematology. Thanks to the co-authors and to the CNAM for the SNDS data. https://lnkd.in/eZRf8ARU #SNDS #RWE #ibrutinib

11

🇫🇷 France's Biopharma Boom: €1.87 Billion Ignites Innovation Engine 🇫🇷 The "Choose France" summit has ignited a €1.87 billion investment surge in the French biopharma industry, fueling a vibrant ecosystem of innovation. Industry titans Sanofi is leading the charge, pledging an additional €1 billion on top of their existing €2.5 billion commitment to bolster biomanufacturing across three key sites in France. This isn't just about expanding capacity; it's about pioneering advancements in biologics, potentially leading to groundbreaking treatments for diseases like type 1 diabetes and chronic obstructive pulmonary disease (COPD). 💡 Beyond Sanofi: A Wave of Investment The French biopharma boom extends beyond a single player. Pfizer is committing €500 million over five years to strengthen its French R&D capabilities, while AstraZeneca is investing €365 million to further enhance its existing facilities at Dunkirk. This surge in investment from established players underscores the growing confidence in France's potential as a global biopharma leader. 🤝 Collaboration: The Secret Ingredient The biopharma boom in France isn't just about financial muscle. A thriving collaborative ecosystem is equally important for fostering innovation and growth. This ecosystem connects established players, innovative startups, and knowledge-sharing organizations like MabDesign, our esteemed partner. 🤝 Partnering for Progress: AnalysisMode and MabDesign Network Through our partnership with MabDesign, we're bringing our cutting-edge AI solutions to the French biopharma market. MabDesign's expertise in biotherapy and biomanufacturing, coupled with our AI-powered bioprocessing advancements, creates a powerful synergy. 💡 A Future Fueled by Innovation The €1.87 billion investment wave, coupled with the collaborative spirit championed by organizations positions France at the forefront of biopharma innovation. We at AnalysisMode are inspired by actively contributing to this exciting chapter, leveraging partnerships to drive progress and accelerate advancements in the field. The future of French biopharma is bright, and it's fueled by a shared commitment to innovation and collaboration. #france #biopharma #biomanfuacturing #investment #analysismode

4

#fundraising 💥 Helical, one of Luxembourg’s most promising AI healthtechs, has just raised a €2.2m Seed to build its open-source platform of bio foundation models, aiming to accelerate pharma research and development. Maxime Allard, co-founder and CTO of Helical tells us more about the platform’s aims, the struggles of getting set up in Luxembourg and why comparisons to #ChatGPT are misguided. 🔗Read the full article here : https://lnkd.in/ePBbb7AD at Silicon Luxembourg #siliconluxembourg #fundraise #healthtech #ai #luxembourg

303

10 commentaires

#womenshealth: In our latest feature, we dive into the transformative journey of Aspivix and their groundbreaking product, Carevix, the world's first clinically proven cervical stabilizer. We had the opportunity to sit down with Mathieu Horras, the visionary behind Aspivix, to discuss how this innovative device is revolutionizing gynecological care by offering a safer, gentler alternative to traditional methods. Join us as we explore how Carevix is significantly reducing pain and bleeding during transcervical procedures, empowering women globally, and setting new standards in women’s health. Read the full article to discover the scientific validation behind Carevix, hear firsthand from patients like Emily from Philadelphia, and learn about Aspivix’s journey from concept to market—a testament to their commitment to women’s healthcare. They also recently announced a groundbreaking achievement in the United States with the first patients benefiting from successful IUD placement and transcervical procedures using the non-traumatic, FDA-approved, cervical stabilizer Carevix™ designed to minimize pain and bleeding and aiming to replace the traditional cervical tenaculum. The first gentle procedures were successfully performed by Alissa M. Conklin, MD. an Assistant Professor of Clinical Obstetrics and Gynecology at Indiana University School of Medicine. 🔗 Don’t miss out on this compelling story. Click here to read the full article and see how Aspivix is making a real difference in the lives of women around the world. https://lnkd.in/ddufYPXg #TechTour2024 #Aspivix #Carevix #womenshealth #healthcareinnovation #empoweringwomen #entrepreneur #entrepreneurship #innovation #tech #techstartup #startups #founder #vc #cvc #venturecapital #women #IUD #gynecology #gynecologicalcare

27

3 commentaires

🔍 Unmet Needs in IBD Treatment and Emerging Therapies : What is the impact of IRA and LoEs for Pharma ? There are still significant unmet needs in the field of Inflammatory Bowel Disease (IBD), but there's good news on the horizon with new treatments emerging. However, for a new biotech player, finding the right positioning and development path can be challenging, given the many treatments already available and the rich pipeline held by big pharma such as AbbVie, J&J, Pfizer, Takeda, BMS Similarly, it can be difficult for investors to understand the true potential of IBD assets. Adding to the complexity is navigating US/EU payer systems for reimbursement, PBMs, considering factors like treatment combinations, biosimilars, and upcoming IRA applications. Genchrome can help you navigate this challenging environment, whether you're investing, licensing, or preparing to launch: contact@genchrome.com #IBD #ulcerativecolitis #CrohnDisease #IRA #LOE #PBM

18

3 commentaires

🔎 𝗔𝗿𝗲 𝘆𝗼𝘂 𝗮 #𝗗𝗧𝘅 𝗼𝗿 #𝗿𝗲𝗺𝗼𝘁𝗲𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝘀𝘁𝗮𝗿𝘁𝘂𝗽 𝘄𝗮𝗻𝘁𝗶𝗻𝗴 𝘁𝗼 𝗴𝗲𝘁 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗶𝗻 𝗙𝗿𝗮𝗻𝗰𝗲? 🗓 Join us this 10th and 11th of June for a unique workshop with the Délégation au numérique en santé (DNS), Haute Autorité de Santé, France Biotech, and Nextep Health to deeply understand #PECAN and other reimbursement paths, including legislation, regulation, and its key stakeholders. Our deep dive will break down how digital medical products can use their clinical data, review their commercialization strategy, and prepare to succeed in the French healthcare market. Our speakers will provide guidance and advice to understand regulatory frameworks, review and strengthen clinical evidence, and how to be fit for PECAN and other reimbursement paths. Join us to meet: 🎤 Corinne Collignon: As the head of the digital health mission department (Haute Autorité de Santé), she has worked for many years in the medical device evaluation department and will provide her experience around the HAS' expectations (clinical evidence, validation, and evaluation of medical devices). 🎤 Pascal Sellier: As the Vice-Chairman of the National Commission for the Evaluation of Medical Devices and Health Technologies at Haute Autorité de Santé, he represents the voice of patients and users in the French healthcare system. 🎤 Stephane Tholander: Currently he is the coordinator of the digital health commission and vice-president of France Biotech. As a serial entrepreneur and Co-Founder/co-CEO of Agora Health and AppThera, he is focused on innovation in healthcare and facilitating the acceleration and adoption of digital medical devices from all angles. 🎤 Vincent Vercamer: With extensive expertise in regulation and market access, he is currently the project director at the French Ministerial Delegation for Digital Health (DNS/Ministère de la Santé) and works closely with the Agence du numérique en santé, responsible for issues relating to #marketaccess and #PECAN. Additionally, he coordinates the G_NIUS platform, supporting innovators in preparing for their reimbursement applications. 🎤 Helene Viatge: With extensive expertise in medical device development and commercialization in France and Europe and founder of AppThera, a clinician platform supporting the prescription of digital therapeutics and enabling patient access. ✅ 𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 𝘯𝘰𝘸 𝘣𝘺 𝘤𝘰𝘯𝘵𝘢𝘤𝘵𝘪𝘯𝘨 𝘰𝘶𝘳 𝘵𝘦𝘢𝘮 𝘰𝘳 𝘴𝘦𝘯𝘥𝘪𝘯𝘨 𝘶𝘴 𝘢 𝘮𝘦𝘴𝘴𝘢𝘨𝘦 𝘷𝘪𝘢 𝘓𝘪𝘯𝘬𝘦𝘥𝘪𝘯 𝘵𝘰 𝘴𝘦𝘤𝘶𝘳𝘦 𝘺𝘰𝘶𝘳 𝘴𝘱𝘰𝘵! #Healthcare #Startups #PECAN #MarketEntry #Regulation #ClinicalEvidence #Workshop #Networking

49

2 commentaires

📄 [Press Release] – MaaT Pharma is proud to announce the successful completion of its Global Offering of 19.2 Million Euros ▪ Support from historical investors Bpifrance, Seventure Partners, Biocodex, and from the management of the Company ▪ 70% of new retail investors previously non-shareholders joined us, showcasing a strong influx of new support, with a total investment of €0.9 million ▪ Financing will enable the Company to extend its cash runway through early Q1 2025 ▪ The net proceeds from the Primary Offering will be used to fund the company’s R&D activities, covering completion of the Phase 3 trial for MaaT013 in Europe, including top-line results/primary endpoint in mid Q4 2024, continuing the pipeline development, including the initiation of Phase 3 trial activities for MaaT013 in the US and the broadening of the Phase 2b trial with MaaT033 across Europe and for working capital and other general corporate purposes, including repayment of current debts. 👉 Read the press release here: https://lnkd.in/efFj8Ube

97

2 commentaires

Great to see the venture build/company creation model gaining more support ( and investment). Many congratulations to General Inception. The concept makes such good business sense, especially in the current investment environment with large investments in later stage opportunities being the trend. This leaves the earlier stages of innovation, (where the future late-stage opportunities originate) needing capitally efficient and creative approaches. We at Cumulus Oncology totally embrace and embody this approach. Great to see visionary investors getting behind this too. The blend of extensive early stage opportunities in Europe coupled with capital and highly experienced mission-focussed teams with successful track records behind them is a winning strategy.

19

[ INTRODUCTION ] 🚀 ATESSIA, Life Science Advisors is the #consulting company that will support you on many of your projects thanks to our consultants #experts in their fields! 🎯The #services offered by Atessia are many: 🔹Regulatory and pharmaceutical strategy 🔹R&D consulting 🔹Consultancy subscription [ASK ATESSIA] 🔹Registration FR & EU from drafting to submission of dossiers 🔹Lifecycle management of marketing authorizations 🔹Regulatory watch [ATESSIA INTELLIGENCE] 🔹Quality system management 🔹Advertising 🔹Vigilances 🔹Training [ATESSIA MASTER CLASS] 🔹Audits 🔹Medical devices 🔹... ✉️ Do you have a project you would like to share with us? Contact us at hello@atessia.fr 💻 Want to find out more about our company, our team or our services? Visit our website: https://lnkd.in/e4r7twpJ #LifeSciences #Advisors #Expertises

5

Discover how the Precellys Evolution Touch & Cryolys Evolution duo is revolutionizing preformulation processes in drug development. Take a look at Bertin Technologies latest article to uncover the efficiency and versatility of these cutting-edge instruments. #Precellys #Cryolys #SamplePrep #Innovation #EfficiencyBoost

9

Navigating regulatory landscapes often feels like a tightrope walk for Healthtech and Medtech companies. France Biotech's study points out a striking contradiction 🤔: while 28% of these firms see regulations as their tallest hurdle in 2023, becoming digital—something seen as a challenge itself—is increasingly becoming the solution to ensure compliance. This duality shows us one clear pathway: embracing technology isn't just about innovation or staying ahead; it's about survival. Regulatory demands are pushing companies towards digitization, making it an inevitable step for those aiming to keep pace with the sector's standards. GxpManager paves the way for a solution tailored to the highly regulated sector, simplifying the journey and easing compliance. Read More >> https://bit.ly/45bBBxu #GxpManager #RegulatoryCompliance #DigitalTransformation

2

🥛 Milk is now making its way into medical therapeutics. Wilk (TLV: WILK), a Yissum portfolio company at The Hebrew University of Jerusalem, has announced its latest partnership with Pluri to develop a novel medical food solution for the elderly: human breast milk-derived food production on a commercial scale. Dr. Nurit Argov-Argaman and her team at Wilk operate the advanced technologies for producing cultured animal milk, cultured human breast milk, and high-grade HMO, personalized to meet consumer's taste, nutritional, and therapeutic needs. Demand for medical food products is rising due to the growing geriatric population, leading this team to discover the oligosaccharides in human breast milk can shape gut microbiota and provide health benefits to adults. Read more about the announcement: https://bit.ly/3wNuJtC If you'd like to learn more about this technology, please reach out to the Business Development contact, Dr. Ilya Pittel, PhD. #StrategicPartnerships #WeAreOne #NoMatterWhat

6

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝟭𝟬 𝗙𝗿𝗲𝗻𝗰𝗵 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝘁𝗵𝗮𝘁 𝗮𝗿𝗲 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝗺𝗲𝗱𝘁𝗲𝗰𝗵 𝘀𝗲𝗰𝘁𝗼𝗿! 👨‍⚕️ 👩‍⚕️ Did you know that in 2023, France Biotech counted 1,393 medtech companies in France? (source: France Biotech). 🇫🇷📈 The medtech sector in France is booming, with innovations transforming healthcare and improving quality of life. Today, we present 10 French gems to watch closely. These startups are at the forefront of medical technology, providing innovative solutions to modern healthcare challenges. 👉 Don’t miss our post on Friday, where we will present the 10 most active VCs in the medtech sector! Subscribe so you don’t miss out. 🔔 Octopize  Ordoclic KLODIOS EUREKAM DiaDeep DrData - Les Docteurs de la donnée BrainTale Robocath PAIRE CybelAngel #Medtech #Startups #Innovation #Health #Technology #Investment #France #Healthcare #TechForGood

55

16 commentaires